NASDAQ:EPZM
Delisted
Epizyme Stock News
$1.47
+0 (+0%)
At Close: Nov 10, 2022
Ipsen to acquire U.S.-based Epizyme for $247 million.
06:12am, Monday, 27'th Jun 2022 MarketWatch
The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020
Ipsen to acquire U.S.-based Epizyme for $247 million.
02:12am, Monday, 27'th Jun 2022
By Joshua Kirby
Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?
03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?
12:47pm, Thursday, 09'th Jun 2022
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
Hot Penny Stocks Under $1 To Watch In June
07:56pm, Thursday, 02'nd Jun 2022 PennyStocks
Penny stocks to watch under $1 right now
The post Hot Penny Stocks Under $1 To Watch In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates
06:28pm, Wednesday, 11'th May 2022 Zacks Investment Research
Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.
Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates
03:48pm, Wednesday, 11'th May 2022
Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates.
Epizyme, Inc. (EPZM) CEO Grant Bogle on Q1 2022 Results - Earnings Call Transcript
02:13pm, Tuesday, 10'th May 2022
Epizyme, Inc. (NASDAQ:EPZM ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Grant Bogle – President and Chief Executive Officer Shefali Agarwal - Senior Medical Advise
Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates
12:15pm, Tuesday, 10'th May 2022 Zacks Investment Research
Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates
09:47am, Tuesday, 10'th May 2022
Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates
10:25pm, Monday, 09'th May 2022 Zacks Investment Research
Bluebird (BLUE) delivered earnings and revenue surprises of -31.75% and 86.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
03:37pm, Monday, 09'th May 2022 Zacks Investment Research
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
12:47pm, Monday, 09'th May 2022
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Epizyme (EPZM) Upgraded to Buy: What Does It Mean for the Stock?
04:00pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Epizyme (EPZM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Epizyme (EPZM) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Tuesday, 03'rd May 2022
Epizyme (EPZM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
